MaxCyte (MXCT)
(Real Time Quote from BATS)
$4.14 USD
+0.11 (2.73%)
Updated Sep 16, 2024 01:42 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
MXCT 4.14 +0.11(2.73%)
Will MXCT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MXCT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MXCT
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Tops Revenue Estimates
Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates
MXCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
MaxCyte (MXCT) is on the Move, Here's Why the Trend Could be Sustainable
Does MaxCyte (MXCT) Have the Potential to Rally 85% as Wall Street Analysts Expect?
Recent Price Trend in MaxCyte (MXCT) is Your Friend, Here's Why
Other News for MXCT
MaxCyte (MXCT) Gets a Buy from Craig-Hallum
MaxCyte touts strategic platform license deal with Kamau Therapeutics
MaxCyte, Kamau Therapeutics enter strategic platform license agreement
MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases
MaxCyte Partners with Kamau Therapeutics to Advance Gene Therapies